126 related articles for article (PubMed ID: 2297586)
21. Autologous bone marrow transplantation for acute leukemia using transplant chemopurified with metabolite of oxazaphosphorines (ASTA Z 7557, INN mafosfamide). First clinical results.
Hervé P; Cahn JY; Plouvier E; Flesch M; Tamayo E; Leconte des Floris R; Peters A
Invest New Drugs; 1984; 2(2):245-52. PubMed ID: 6381384
[TBL] [Abstract][Full Text] [Related]
22. ASTA Z 7557 (INN mafosfamide) for the in vitro treatment of human leukemic bone marrows.
Douay L; Gorin NC; Laporte JP; Lopez M; Najman A; Duhamel G
Invest New Drugs; 1984; 2(2):187-90. PubMed ID: 6381382
[TBL] [Abstract][Full Text] [Related]
23. Plasma interacts with mafosfamide toxicity to normal haematopoietic progenitor cells: impact on in vitro marrow purging.
Giarratana MC; Gorin NC; Douay L
Nouv Rev Fr Hematol (1978); 1995; 37(2):125-30. PubMed ID: 7644349
[TBL] [Abstract][Full Text] [Related]
24. [A simple method for detecting immature precursors after in vitro bone marrow treatment with ASTA-Z 7654].
Lamana M; Fernández-Rañada JM
Sangre (Barc); 1991 Dec; 36(6):501-3. PubMed ID: 1812583
[TBL] [Abstract][Full Text] [Related]
25. The synthetic tetrapeptide AcSDKP protects cells that reconstitute long-term bone marrow stromal cultures from the effects of mafosfamide (Asta Z 7654).
Genevay MC; Mormont C; Thomas F; Berthier R
Exp Hematol; 1996 Jan; 24(1):77-81. PubMed ID: 8536796
[TBL] [Abstract][Full Text] [Related]
26. In vitro purging of bone marrow with mafosfamide synergizes with in vivo chemotherapy to delay the hematological recovery in a murine model of autologous bone marrow transplantation.
Lopez M; Mary JY; Sainteny F
Exp Hematol; 1993 Feb; 21(2):311-8. PubMed ID: 8425567
[TBL] [Abstract][Full Text] [Related]
27. Comparative cytotoxicity of various drug combinations for human leukemic cells and normal hematopoietic precursors.
Chang TT; Gulati S; Chou TC; Colvin M; Clarkson B
Cancer Res; 1987 Jan; 47(1):119-22. PubMed ID: 3466686
[TBL] [Abstract][Full Text] [Related]
28. Cumulative chemotherapy increases mafosfamide toxicity for normal progenitor cells in AML patients: rationale for cryopreserving adapted-dose purged marrow early in first complete remission.
Martin H; Bruecher J; Claudé R; Hoelzer D
Bone Marrow Transplant; 1993 Nov; 12(5):495-9. PubMed ID: 8298560
[TBL] [Abstract][Full Text] [Related]
29. Comparative in vitro effects of cyclophosphamide derivatives on murine bone marrow-derived stromal and hemopoietic progenitor cell classes.
de Jong JP; Nikkels PG; Brockbank KG; Ploemacher RE; Voerman JS
Cancer Res; 1985 Sep; 45(9):4001-5. PubMed ID: 3896474
[TBL] [Abstract][Full Text] [Related]
30. In vitro evaluation of combination drug purging for autologous bone marrow transplantation.
Jones RJ; Miller CB; Zehnbauer BA; Rowley SD; Colvin OM; Sensenbrenner LL
Bone Marrow Transplant; 1990 May; 5(5):301-7. PubMed ID: 2350626
[TBL] [Abstract][Full Text] [Related]
31. Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination.
Lemoli RM; Gasparetto C; Scheinberg DA; Moore MA; Clarkson BD; Gulati SC
Blood; 1991 Apr; 77(8):1829-36. PubMed ID: 2015406
[TBL] [Abstract][Full Text] [Related]
32. Establishment of a reliable experimental procedure for bone marrow purging with mafosfamide (ASTA Z 7557).
Douay L; Mary JY; Giarratana MC; Najman A; Gorin NC
Exp Hematol; 1989 Jun; 17(5):429-32. PubMed ID: 2653856
[TBL] [Abstract][Full Text] [Related]
33. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
34. Comparative heat sensitivity of murine and human hemopoietic progenitors and clonogenic leukemia cells.
Gidáli J; Fehér I; Kovács P
Stem Cells; 1994 Sep; 12(5):533-8. PubMed ID: 7804126
[TBL] [Abstract][Full Text] [Related]
35. Effect of the aldehyde dehydrogenase inhibitor, cyanamide, on the ex vivo sensitivity of murine multipotent and committed hematopoietic progenitor cells to mafosfamide (ASTA Z 7557).
Kohn FR; Landkamer GJ; Sladek NE
Immunopharmacol Immunotoxicol; 1987; 9(2-3):163-76. PubMed ID: 3437102
[TBL] [Abstract][Full Text] [Related]
36. Enhanced selectivity of hyperthermic purging of human progenitor cells using Goralatide, an inhibitor of cell cycle progression.
Wierenga PK; Brenner MK; Konings AW
Bone Marrow Transplant; 1998 Jan; 21(1):73-8. PubMed ID: 9486498
[TBL] [Abstract][Full Text] [Related]
37. Toxicity of ASTA Z 7557 (INN mafosfamide) to normal- and leukemic stem cells: implications for autologous bone marrow transplantation.
Hagenbeek A; Martens AC
Invest New Drugs; 1984; 2(2):237-43. PubMed ID: 6381383
[TBL] [Abstract][Full Text] [Related]
38. Clonogenic leukemic progenitor cells in acute myelocytic leukemia are highly sensitive to cryopreservation: possible purging effect for autologous bone marrow transplantation.
Allieri MA; Lopez M; Douáy L; Mary JY; NGuyen L; Gorin NC
Bone Marrow Transplant; 1991 Feb; 7(2):101-5. PubMed ID: 2049553
[TBL] [Abstract][Full Text] [Related]
39. Combinations of 4-hydroperoxycyclophosphamide (4-HC) and cisplatin for bone marrow purging in autologous marrow transplantation: an update.
Peters RH; Brandon CS; Avila LA; Gale GR; Stuart RK
Prog Clin Biol Res; 1990; 333():57-68. PubMed ID: 2309001
[TBL] [Abstract][Full Text] [Related]
40. No preferential sensitivity of clonogenic AML cells to ASTA-Z-7557.
Kluin-Nelemans HC; Martens AC; Löwenberg B; Hagenbeek A
Leuk Res; 1984; 8(4):723-8. PubMed ID: 6590937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
